140 related articles for article (PubMed ID: 33790098)
21. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
23. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
24. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab biosimilar shows potential for breast cancer.
Baker H
Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154
[No Abstract] [Full Text] [Related]
27. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of action of the trastuzumab biosimilar CT-P6.
Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
[No Abstract] [Full Text] [Related]
29. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
30. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
32. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
33. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
Jeon C; Kang SH; Kim SB; Paik NS; Lee I; Kim SK; Kim EY; Son GS; Yoo YB; Lee KH; Shin J; Ju S; Jang H; Park MH
Oncology; 2024; 102(6):465-475. PubMed ID: 37899039
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract][Full Text] [Related]
35. Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
Stebbing J; Baranau Y; Manikhas A; Lee SJ; Thiruchelvam P; Leff D; Esteva FJ
Expert Rev Anticancer Ther; 2018 Jun; 18(6):531-541. PubMed ID: 29580109
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
37. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.
Thompson LM; Eckmann K; Boster BL; Hess KR; Michaud LB; Esteva FJ; Hortobágyi GN; Barnett CM
Oncologist; 2014 Mar; 19(3):228-34. PubMed ID: 24536030
[TBL] [Abstract][Full Text] [Related]
38. Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
Kolberg HC; Colleoni M; Demetriou GS; Santi P; Tesch H; Fujiwara Y; Tomasevic Z; Hanes V
Drug Saf; 2020 Mar; 43(3):233-242. PubMed ID: 31927716
[TBL] [Abstract][Full Text] [Related]
39. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab.
Goto E; Hata T; Nishihara M; Neo M; Iwamoto M; Kimura K; Goto M; Rikitake Y
Br J Clin Pharmacol; 2023 Jul; 89(7):2102-2112. PubMed ID: 36709967
[TBL] [Abstract][Full Text] [Related]
40. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]